Literature DB >> 21396171

Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1β and TNF-α.

Shinichi Matsumoto1, Morihito Takita, Damien Chaussabel, Hirofumi Noguchi, Masayuki Shimoda, Koji Sugimoto, Takeshi Itoh, Daisuke Chujo, Jeff SoRelle, Nicholas Onaca, Bashoo Naziruddin, Marlon F Levy.   

Abstract

Poor efficacy is one of the issues for clinical islet transplantation. Recently, we demonstrated that pancreatic ductal preservation significantly improved the success rate of islet isolation; however, two transplants were necessary to achieve insulin independence. In this study, we introduced iodixanol-based purification, thymoglobulin induction, and double blockage of IL-1β and TNF-α as well as sirolimus-free immunosuppression to improve the efficacy of clinical islet transplantation. Nine clinical-grade human pancreata were procured. Pancreatic ductal preservation was performed using ET-Kyoto solution in all cases. When the isolated islets met the clinical criteria, they were transplanted. We utilized two methods of immunosuppression and anti-inflammation. The first protocol prescribed daclizumab for induction, then sirolimus and tacrolimus to maintain immunosuppression. The second protocol used thymoglobulin for induction and tacrolimus and mycophenolate mofetil to maintain immunosuppression. Eternacept and anakinra were administered as anti-inflammatory drugs. The total amount of insulin required, HbA1c, and the SUITO index were determined to analyze and compare the results of transplantation. All isolated islet preparations (9/9) met the criteria for clinical transplantation, and they were transplanted into six type 1 diabetic patients. All patients achieved insulin independence with normal HbA1c levels; however, the first protocol required two islet infusions (N = 3) and the second protocol only required a single infusion (N = 3). The average SUITO index, at 1 month after a single-donor islet transplantation, was significantly higher in the second protocol (49.6 ± 8.3 vs. 19.3 ± 6.3, p < 0.05). Pancreatic ductal preservation, iodixanol-based purification combined with thymoglobulin induction, and blockage of IL-1β and TNF-α as well as sirolimus-free immunosuppression dramatically improved the efficacy of clinical islet transplantations. This protocol enabled us to perform successful single-donor islet transplantations. Further large-scale studies are necessary to confirm these results and clarify the mechanism of each component.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396171     DOI: 10.3727/096368910X564058

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  53 in total

1.  Improvement of collagenase distribution with the ductal preservation for human islet isolation.

Authors:  Masayuki Shimoda; Takeshi Itoh; Koji Sugimoto; Shuichi Iwahashi; Morihito Takita; Daisuke Chujo; Jeffery A Sorelle; Bashoo Naziruddin; Marlon F Levy; Paul A Grayburn; Shinichi Matsumoto
Journal:  Islets       Date:  2012-03-01       Impact factor: 2.694

2.  Impact of tissue volume and purification on clinical autologous islet transplantation for the treatment of chronic pancreatitis.

Authors:  Shinichi Matsumoto; Morihito Takita; Masayuki Shimoda; Koji Sugimoto; Takeshi Itoh; Daisuke Chujo; Jeffery A SoRelle; Yoshiko Tamura; Ana M Rahman; Nicholas Onaca; Bashoo Naziruddin; Marlon F Levy
Journal:  Cell Transplant       Date:  2012-02-02       Impact factor: 4.064

Review 3.  State of the art of clinical islet transplantation and novel protocols of immunosuppression.

Authors:  A M James Shapiro
Journal:  Curr Diab Rep       Date:  2011-10       Impact factor: 4.810

Review 4.  Strategies toward single-donor islets of Langerhans transplantation.

Authors:  A M James Shapiro
Journal:  Curr Opin Organ Transplant       Date:  2011-12       Impact factor: 2.640

5.  Current status of clinical islet transplantation.

Authors:  Andrew R Pepper; Boris Gala-Lopez; Oliver Ziff; Am James Shapiro
Journal:  World J Transplant       Date:  2013-12-24

Review 6.  Biologic agents in islet transplantation.

Authors:  Boris Gala-Lopez; Andrew R Pepper; A M James Shapiro
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

7.  How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology?

Authors:  Marco Carbone; Jan Lerut; James Neuberger
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 8.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

9.  Autoimmune chronic pancreatitis with IgG4-related pancreatic pseudocyst in a patient undergoing total pancreatectomy followed by autologous islet transplantation: a case report.

Authors:  Morihito Takita; Takeshi Itoh; Shinichi Matsumoto; Masayuki Shimoda; Daisuke Chujo; Shuichi Iwahashi; Yoshiko Tamura; Nicholas Onaca; Bashoo Naziruddin; Bryan L Bartlett; Marlon F Levy
Journal:  Pancreas       Date:  2013-01       Impact factor: 3.327

10.  Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.

Authors:  Morihito Takita; Shinichi Matsumoto; Masayuki Shimoda; Daisuke Chujo; Takeshi Itoh; Jeffrey A Sorelle; Kerri Purcell; Nicholas Onaca; Bashoo Naziruddin; Marlon F Levy
Journal:  Clin Transplant       Date:  2012 Sep-Oct       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.